The Real-World use of McGill interactive pediatric OncoGenetic guidelines (MIPOGG): A Cross-Sectional survey

Clicks: 5
ID: 323588
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #24 of 329 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 329 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Cancer predisposition syndrome (CPS) recognition is complex, time-sensitive, and requires integration of cancer features with personal and family history in an evolving genetic landscape. The McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG) is a validated CPS screening web/app-based tool with expanding global reach and users from 98 countries. Given MIPOGG's unrestricted availability, we aimed to characterize self-reported use across clinical, education, and research contexts. METHODS: We conducted a cross-sectional, web-based mixed-methods survey of MIPOGG newsletter subscribers (n = 1,749). The questionnaire captured demographics, self-reported MIPOGG use patterns across clinical, education, and research domains, as well as levels of trust and adherence with MIPOGG's content. Descriptive quantitative analyses were complemented with qualitative data from open-ended questions. RESULTS: Ninety responses were obtained from MIPOGG users (physicians n = 63, genetic counsellors n = 20, others n = 7) across 23 countries. MIPOGG was predominantly used for clinical purposes (89.4%), regardless of role or field of practice. Respondents used MIPOGG to guide decisions for genetic referrals (82.2%) and testing (84.9%). Among clinical users, 52.1% followed MIPOGG's recommendations most of the time, and 23.3% adhered when it matched their clinical judgment. MIPOGG was used for educational and research purposes in 72.9% and 28.2% of respondents, respectively. Guidance for prioritization/triage, differential diagnoses, and use as a "safety net" were common themes raised in the qualitative data. CONCLUSION: MIPOGG is predominantly used in clinical practice where it guides genetic referral and testing decisions for users within and outside genetic-based practices. Reported adherence to MIPOGG underscores the importance of accountability, transparent oversight, and efforts to optimize its performance.
Reference Key
openalex_W7172412946 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Javier Higuera‐Ornelas, M. Martínez, Lara Reichman, Crystal Budd, Leah C. Hammond, Alana J. Mistry, Michelle Carter, Tania Cruz Mariño, Laura Palma, Yvonne Bombard, Claudie Saulnier, Catherine Goudie
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag272
URL
https://doi.org/10.1093/jnci/djag272
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.